NCT00816517

Use of Botulinum Toxin to Treat Psoriasis

Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: University of Minnesota · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation. Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions. This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
BIOLOGICAL	injection of botulinum toxin type A.	35 to 100 units injected around a skin lesion (plaque) one time.

Timeline

• Start date: 2009-01-01
• Primary completion: 2015-06-01
• Completion: 2015-12-01
• First posted: 2009-01-01
• Last updated: 2016-04-04

Locations

1 site across 1 country: United States